Clinical Research
Cincinnati Eye Institute is home to one of the largest and most prestigious private-sector clinical research departments in ophthalmology in the United States. The eye doctors and research staff at CEI have been conducting clinical research for more than 35 years and have participated in over 300 research studies. Our goal is to pave the way for tomorrow’s eye care and bring it to our patients today.
Current Clinical Studies
Spyglass (SGP-005)
Glaucoma Surgical Device
A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System used in combination with the SpyGlass IOL
- Physician: Anup Khatana, MD
- Location: 1945 CEI Drive, Cincinnati, OH 45242
- Coordinator: Meagana Wilkins, (513) 569-3285
Abbvie (M22-087)
Glaucoma Surgical Device
A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Subjects with Glaucoma
- Physician: Daniel Hammer, MD
- Location: 1945 CEI Drive, Cincinnati, OH 45242
- Coordinator: Lee Stokes, (513) 569-3213
Mass General (ExCrossV)
Surgical corneal transplant
ExCrossV ExVivo Corneal Crosslinking of Donor Corneal Tissue for Vascularized High-Risk Keratoplasty
- Physician: Kavitha Sivaraman, MD
- Location: 1945 CEI Drive, Cincinnati, OH 45242
- Coordinator: Meagana Wilkins, (513) 569-3285
Regeneron (Sienna R33918-AMD-2326)
Subcutaneous Injection for patients with Geographic Atrophy due to Age-related macular degeneration
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (AMD)
- Physician: Robert Foster, MD
- Location: 9997 Carver Road, Cincinnati, OH 45242
- Coordinator: Mason Adams, (513) 569-3787
EyeBio Technologies (MK-8748-002)
Injection trial for wet-AMD
A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared with Intravitreal Aflibercept (2 mg) in Participants with Neovascular Age-Related Macular Degeneration (NVAMD)
- Physician: Daniel Miller, MD
- Location: 9997 Carver Road, Cincinnati, OH 45242
- Coordinator: Novale Manning, (513) 569-3170
Opus Genetics (OPGx_BEST1 DUO-1001)
Surgical Gene Therapy for BEST-1 Disease
A Phase 1b/2a, Open-Label, Dose-Exploration Basket Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-BEST1 Administered in Patients with Either Autosomal-Dominant BEST1 Disease (Best Vitelliform Macular Dystrophy [BVMD]) or Autosomal-Recessive Bestrophinopathy (ARB)
- Physician: Robert Sisk, MD
- Location: 9997 Carver Road, Cincinnati, OH 45242
- Coordinator: Novale Manning, (513) 569-3170
Astellas (2020-CL-0102)
Natural History Study for Stargardt’s Disease
An Observational Study of Natural Disease Progression in Participants with Macular Dystrophies Expressing a Stargardt-type Clinical Presentation
- Physician: Robert Sisk, MD
- Location: 9997 Carver Road, Cincinnati, OH 45242
- Coordinator: Mason Adams, (513) 569-3787
Astellas (2020-CL-0101)
Surgical Cell Therapy Study for Stargardt’s Disease
A Phase 1b, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Subretinal Dose of ASP2020 in Participants with Macular Dystrophies with a Stargardt-type Clinical Presentation
- Physician: Robert Sisk, MD
- Location: 9997 Carver Road, Cincinnati, OH 45242
- Coordinator: Mason Adams, (513) 569-3787
Cincinnati Eye Institute (PLANE)
Intravitreal Injection Study for Presumed Ocular Histoplasmosis (POHS)
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome [PLANE Study]
- Physician: Miguel Busquets, MD
- Location: 9997 Carver Road, Cincinnati, OH 45242
- Coordinator: Meagana Wilkins, (513) 569-3285
Merck (MK-8748-004)
Intravitreal Injection Study for Diabetic Macular Edema (DME)
A Randomized, Double-Masked, Multicenter, 3 Arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of intravitreal (IVT) MK-8748 Compared to Aflibercept (2 mg) in Participants with Diabetic Macular Edema (DME)
- Physician: James Osher, MD
- Location: 9997 Carver Road, Cincinnati, OH 45242
- Coordinator: Noah Wendt, (513) 569-3479
Meet Our Clinical Research Team
Megan Kingdon
Director of Clinical Research
EyeCare Partners
Kelye Conrad
Clinical Research Manager, Ohio Region
EyeCare Partners
How Does Clinical Research Help Our Patients?
Thousands of patients with eye problems come to CEI each week to find leading-edge solutions to their eye care needs. In addition to patients from Ohio and Northern Kentucky, we see patients who travel from all over the nation to see our eye care experts. Our participation in clinical research allows us to offer patients the most advanced treatment options possible.
Staying on the Leading Edge of Eye Care Research
Our on-going commitment to physician-controlled eye care research enables us:
- To provide patients with new treatment options
- To be at the forefront of vision care advances
- To create an environment for lifelong learning and advancement
- To advance the future of eye health and vision
Contact Cincinnati Eye Institute
Do you have questions about ongoing clinical research at Cincinnati Eye Institute? Complete the form below to join our research registry, and a member of our team will contact you to discuss any questions you may have about active clinical trials.
Research Registry
The doctors at Cincinnati Eye Institute have either authored or reviewed the content on this site.
New treatment for Dry Macular Degeneration (AMD) via the Valeda Light Delivery system